Trial Profile
A Phase I clinical trial of TFC-039 for the treatment of Type 2 diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs TFC-039 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 30 Jun 2021 Status changed from recruiting to completed, according to a Sirona Biochem media release.
- 03 Jul 2019 According to a Sirona Biochem media release, this trial is progressing on schedule with no adverse events.
- 03 Jul 2019 Status changed from planning to recruiting, according to a Sirona Biochem media release.